Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Posterior Cortical Atrophy (PCA) is a rare progressive neurodegenerative disorder with a typical onset between 50-65 years of age characterized by progressive impairment of higher visual processing skills and other posterior cortical functions without any evidence of ocular abnormalities.
Features include very common findings: Oculomotor apraxia, Anxiety, Ataxia, and Confusion and others; and common findings: Abnormality of vision, Color vision defect, Photophobia, and Dyslexia and others. 21 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Anxiety, Ataxia, Cerebral visual impairment |
Biomarker and diagnostic research for posterior cortical atrophy has been reported in the published literature.
Phenotype severity distribution: 10 very common features, 5 common features.
Estimated prevalence: Unknown (Unknown prevalence).
7 clinical trials registered, 4 recruiting. Interventions under study include medical devices, drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE2, 5 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02740634](https://clinicaltrials.gov/study/NCT02740634) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Eyes
5 |
Oculomotor apraxia, Cerebral visual impairment, Abnormality of vision |
Arms and legs | 2 | Finger agnosia, Limb apraxia |
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study |
NA |
Mayo Clinic |
RECRUITING |
[NCT04150198](https://clinicaltrials.gov/study/NCT04150198) | MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY | NA | Institut National de la Santé Et de la Recherche Médicale, France | UNKNOWN |
[NCT07222605](https://clinicaltrials.gov/study/NCT07222605) | Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device | NA | eQ8Health Corporation d/b/a CareONE Concierge | ENROLLING_BY_INVITATION |
[NCT04576793](https://clinicaltrials.gov/study/NCT04576793) | Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease | PHASE2 | Columbia University | RECRUITING |
[NCT07191327](https://clinicaltrials.gov/study/NCT07191327) | Testing Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) as a Treatment of Posterior Cortical Atrophy | NA | University of Michigan | RECRUITING |
27 publications have been identified in PubMed for posterior cortical atrophy. Research spans Basic Science / Preclinical (33%), Review / Meta-Analysis (22%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 9 | 33% |
Research summaries | 6 | 22% |
Patient case studies | 5 | 19% |
Disease patterns and progression | 5 | 19% |
Testing and diagnosis research | 2 | 7% |
Nunes Rato R (2025). [PMID: 40384358](https://pubmed.ncbi.nlm.nih.gov/40384358/). *Mov Disord Clin Pract*. [Basic Science / Preclinical]
Bux T (2025). [PMID: 40469807](https://pubmed.ncbi.nlm.nih.gov/40469807/). *S Afr J Psychiatr*. [Case Report / Case Series]
Miller ZA (2025). [PMID: 40959879](https://pubmed.ncbi.nlm.nih.gov/40959879/). *Alzheimers Dement*. [Epidemiology / Natural History]
Henderson SK (2025). [PMID: 41102738](https://pubmed.ncbi.nlm.nih.gov/41102738/). *Alzheimers Res Ther*. [Epidemiology / Natural History]
Abdi Z (2025). [PMID: 40174910](https://pubmed.ncbi.nlm.nih.gov/40174910/). *Neuropathol Appl Neurobiol*. [Basic Science / Preclinical]
Barnard L (2025). [PMID: 40577677](https://pubmed.ncbi.nlm.nih.gov/40577677/). *Neurology*. [Basic Science / Preclinical]
Lu J (2025). [PMID: 40019732](https://pubmed.ncbi.nlm.nih.gov/40019732/). *Ann Nucl Med*. [Basic Science / Preclinical]
Suárez-González A (2025). [PMID: 39515839](https://pubmed.ncbi.nlm.nih.gov/39515839/). *Pract Neurol*. [Review / Meta-Analysis]
Bouteloup V (2025). [PMID: 40181683](https://pubmed.ncbi.nlm.nih.gov/40181683/). *JAMA Neurol*. [Epidemiology / Natural History]
Singh-Reilly N (2025). [PMID: 40056539](https://pubmed.ncbi.nlm.nih.gov/40056539/). *Neurobiol Aging*. [Review / Meta-Analysis]
AI-curated news mentioning posterior cortical atrophy
Updated Jul 30, 2026
A multi-case review highlights the clinical features and neuropsychological profiles of patients with posterior cortical atrophy. This study contributes to the understanding of cognitive impairments associated with this rare condition.
A recent study published in PubMed explores the distribution of neurofibrillary tangles in posterior cortical atrophy compared to typical early-onset Alzheimer's disease. This research may enhance understanding of disease progression and pathology in these conditions.